OxTalks is Changing
OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Therapeutic Targeting of the DNA Damage Response
Please contact adminsupport@oncology.ox.ac.uk for Microsoft Teams link
Dr. Graeme Smith is the Chief Scientific Officer at Artios Pharma with responsibility for the scientific strategy and drug discovery projects in the DNA Damage Response (DDR) area. Prior to Artios, Dr. Graeme Smith held the positions of Senior Project Leader and Executive Director of Bioscience at AstraZeneca within the Oncology therapy area. In these roles Dr. Smith led teams in the discovery and development of novel anti-cancer agents delivering novel therapies into the clinic. Dr. Smith was Research Director at KuDOS Pharmaceuticals where he was a co-inventor of Lynparza™ (olaparib), the first PARP inhibitor to reach the market in 2014.
Date:
5 June 2023, 11:00
Venue:
Venue to be announced
Speakers:
Speaker to be announced
Organising department:
Department of Oncology
Organiser:
Annabelle Ziegler
Organiser contact email address:
adminsupport@oncology.ox.ac.uk
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Yuliia Karpenko
